ArticleEpidemiology and health2018
Tuberculosis control in the Republic of Korea.
Article in Epidemiology and health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Changes in Sero-immunological Status for Infectious Diseases in Solid Organ Transplantation: A 20-Year Single-Center Study in Korea.Annals of laboratory medicine · 2026Article
- Comparative analysis of lung cancer risk factors between never-smokers and heavy smokers: a nationwide population-based study in Korea.Translational lung cancer research · 2026Article
- Factors associated with extended treatment duration in patients with drug-susceptible pulmonary tuberculosis: a prospective multicentre cohort study in South Korea.BMC infectious diseases · 2026Article
- Incidence of active tuberculosis in Korean patients with rheumatoid arthritis: a comparison between tumor necrosis factor inhibitors and tofacitinib.Journal of rheumatic diseases · 2026Article
- Long-Term Trends and Determinants of Tuberculosis Burden in China, 1990-2023: Insights from the Global Burden of Disease Study 2023.Pathogens (Basel, Switzerland) · 2026Article
- Modelling tuberculosis transmission dynamics in Malaysia.Frontiers in public health · 2026Article
- Clinical Indicators Distinguishing Pulmonary Tuberculosis from Community-Acquired Pneumonia in Older Adults: A Prospective Multicenter Study.Pathogens (Basel, Switzerland) · 2025Observational
- Epidemiology and Clinical Characteristics of Community-Acquired Pneumonia in Hospitalized Patients at a Single Tertiary Center in Korea.Journal of Korean medical science · 2025Article
- Risk Factors for Latent Tuberculosis Identified Using Epidemiological Investigation in Congregate Settings of Gyeongsan City, Republic of Korea (2014-2023).Pathogens (Basel, Switzerland) · 2025Article
- Analysis of nationwide adverse event reports on Isoniazid and Rifampin in tuberculosis prevention and treatment in South Korea.Scientific reports · 2025Article
- [Characteristics and Trends of Tuberculosis Deaths in 2023: An Analysis of Cause-of-death Statistics from Statistics Korea].Jugan geon-gang gwa jilbyeong · 2025Article
- Discrepancies in tuberculosis burden estimates: North Korean defectors vs. official reports.Frontiers in public health · 2025Article
- Latent tuberculosis infection in China, 1990-2050: GBD-informed projections for age-targeted screening.Frontiers in public health · 2025Article
- Association of serum complement C3 level with disease severity in primary pterygium.Frontiers in medicine · 2025Article
- Determinants of the lost to follow-up status among patients with tuberculosis who emigrated to the Republic of Korea: a mixed-method study.Frontiers in public health · 2025Article
- Baseline lung function and risk of incident tuberculosis: a nationwide population-based cohort study.PloS one · 2025Article
- Impact of Mass Screening Using Chest X-Ray on Mortality Reduction and Treatment Adherence Among Pulmonary Tuberculosis Patients.Journal of Korean medical science · 2024Article
- Identifying Predictors of Unfavorable Treatment Outcomes in Tuberculosis Patients.International journal of environmental research and public health · 2024Article
- Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis.Rheumatology and therapy · 2024Article
- Incidence of Tuberculosis Among Immigrants in Korea Who Participated in a Latent Tuberculosis Infection Screening Program.Journal of Korean medical science · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and mortality rates of tuberculosis (TB) in the Republic of Korea are 77 and 5.2 per 100,000 people, respectively (2016), which are the highest among the member countries of the Organization for Economic Cooperation and Development. Recently, the incidence of TB among teens and individuals in their 20s in the Republic of Korea decreased significantly. The decrease is largely attributed to the TB screening and contact investigation efforts targeting schools over the past few years. However, the incidence of TB among elderly individuals remains high, and it is even increasing compared to that in the past 10 years. Older individuals account for 42% of all TB cases and 82% of TB-related deaths. The success rate of TB treatment in the Republic of Korea has gradually increased due to various programs, such as control of non-compliance, insurance coverage for TB diagnosis and treatment, and TB public-private mix models. This study suggests that policy makers should focus their efforts on policies that prioritize a significant reduction in the incidence of TB based on the 2nd National Strategic Plan for Tuberculosis Control (2018-2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.